key: cord-0839139-m8z6s0ef authors: Farina, B.; Massullo, C.; De Rossi, E.; Carbone, G.A.; Serraino, R.; Imperatori, C. title: Psychotropic medications sales during COVID-19 outbreak in Italy changed according to the pandemic phases and related lockdowns date: 2021-10-16 journal: Public Health DOI: 10.1016/j.puhe.2021.10.005 sha: 3e7590bbfbe4d00fa72073831af6a055d4e6b766 doc_id: 839139 cord_uid: m8z6s0ef OBJECTIVES: We have investigated the psychotropic medications sales (i.e. benzodiazepines, mood stabilisers and selective serotonin reuptake inhibitors) during the COVID-19 pandemic in the period from March 2020 to February 2021 compared with the same period in the preceding year. STUDY DESIGN: This was a retrospective and observational study. METHODS: Data were obtained from five pharmacies located in a working-class zone populated by approximately 150,000 people in the urban area of Rome (Italy). RESULTS: A general slight increase in psychotropic medications sales was observed during the whole pandemic period compared with the previous year. CONCLUSION: Our data showed that (1) the percentage of sales seems to vary according to the pandemic phases and related lockdowns and (2) the sales differ between the classes of medications considered. Epidemiological studies, reviews and meta-analyses demonstrate the worsening of mental health status during the COVID-19 pandemic compared with previous periods. 1, 2 Indeed, it has been reported an increased prevalence of mood-, anxiety-, sleep-and stress-related disorders due to an interplay of several factors such as worry about becoming infected, worsening living conditions caused by forced quarantine and nationwide lockdowns, social isolation, reduced income, school and university closures, dramatic changes in work life. 1e3 Nevertheless, data on psychotropic medications consumption during COVID-19, as a possible effect of the increased burden of psychological suffering, are still scarce and controversial. Some national and government agencies worldwide report a global growth of prescriptions of benzodiazepines (BZDs), mood stabilisers (MSs) and selective serotonin reuptake inhibitors (SSRIs) during the COVID-19 pandemic, 4,5 but it is still unclear the role of the different factors involved in this increase. For example, Armitage 4 attributes the increased rate of antidepressant prescribing during the first COVID-19 lockdown measured by the National Health Service in England to the negative psychological impact of the pandemic, whereas Walker et al. 6 contested this hypothesis considering this increase as a consequence of the ongoing upward trend in antidepressants prescribing over the last years, independently from the COVID-19. The official government Italian National Pharmaceutical Agency (AIFA) 7 detected an increase (þ7.96%) in sales of 'anxiolytics' in the pandemic period compared with the preceding year. Nevertheless, the AIFA does not specify which pharmacological classes of 'anxiolytics' were considered. To extend available data on psychotropic drugs consumption during COVID-19 pandemic, we assessed the monthly sales of BZDs, MSs and SSRIs in a working-class zone populated by about 150,000 people in the urban area of Rome (Italy) in the period from March 2020 to February 2021 compared with the same period in the preceding year. According to the aims of the present study, the sales of three classes of psychotropic medications used in the treatment of anxiety-depressive spectrum have been investigated: BZDs, MSs and SSRIs. The therapeutic classes have been selected according to the European Pharmaceutical Market Research Association. Data were obtained from five pharmacies located in a working-class zone populated by approximately 150,000 people in the urban area of Rome (Italy). The average monthly number of customers (i.e. the number of individuals who bought at least one medication or another non-pharmaceutical health-related product) in these pharmacies is approximately 28,000 people. Considering the cyclical nature of COVID-19 being characterised by peaks and waves, 8 As expected, the first result detected was the decrease in the number of pharmacy customers during the first and the second COVID-19 waves compared with the same period in the previous year (Fig. 1A) Focusing on the considered time points, compared with the previous year, an increase in all considered psychotropic medications sales (20,574 vs 19,432; i.e. þ5.88%) was observed during the pandemic period at T2 (Fig. 1B) . Conversely, a decrease was observed during the pandemic period at T1 (14,410 vs 15,259; i.e. À5.56%) and T3 (25,003 vs 25,237; i.e. À0.93%). Considered separately (Fig. 1CeE) , an increase in BDZs (11,307 vs 11,094; i.e. þ1.92%), MSs (3,385 vs 2,967; i.e. þ14.09%) and SSRIs (5,882 vs 5,371; i.e. þ9.51%) sales was observed during the pandemic period at T2. An increase in SSRIs (7,177 vs 6,879; i.e. þ4.33%) and MSs (4,076 vs 3,798; i.e. þ7.32%) sales was also observed during the pandemic period at T3. Conversely, a decrease in BDZs (13,750 vs 14,560; i.e. À5.56%) sales was detected during the pandemic period at T3. Finally, a decrease in BDZs (8,292 vs 8,733; i.e. À5.05%), SSRIs (3,785 vs 4,162; i.e. À9.06%) and MSs (2,333 vs 2,364; i.e. À1.31%) sales was observed during the pandemic period at T1. The aim of this study was to investigate the BDZs, SSRIs and MSs consumption during COVID-19 outbreak in a sample of the urban area of Rome (Italy). As official government data are still not available in detail, to the best of our knowledge, this is the first study conducted in Italy on psychotropic medications consumption during the first year of the COVID-19 pandemic. The most relevant results of our study are that (1) the percentage of sales seems to vary according to the pandemic phases and related lockdowns and (2) the sales differ between the classes of medications considered. Indeed, even if we observed a general increase in SSRIs (þ2.63%) and MSs (þ7.28%) sales during the COVID-19 year (March 2020 to February 2021) compared with the previous one (March 2019 to February 2020), this growth varies according to the restriction phases with an initial decrease in T1 and an upsurge in T2 and T3. The initial decrease can be explained by both the substantial reduction of pharmacy customers (À18.46%) observed at the first lockdown period (T1) and the disruption of mental health services during COVID-19 lockdown. 9 We should recall that the acute outbreak of March 2020 induced the Italian government to enforce the first total lockdown in the Western world. People were not allowed to circulate, and the most of non-essential public and private health services were closed to avoid the spread of the infection. Unavailability of health services and prescriptions, as well as the worry of being infected, can explain the initial reduction of medication consumptions. On the contrary, in T2 (summertime), the situation was temporarily normalised, and the restrictions were discontinued. In T2, we do not observe relevant differences with the same period of 2019 in the number of pharmacies customers, but the consumption of the psychotropic medications raised for all the classes considered (BDZs þ1.92%, MSs þ14.09% and SSRIs þ9.51%). In the second Italian lockdown (T3), which in Italy has been experienced with much more discouragement than the first, even if the customers number decreased (À7.45%), we detected an increase in SSRIs (þ4.33%) and MSs (þ7.32%) consumptions. We can, thus, hypothesise that reduced mental health resources and growth of distressing conditions 1e3 led to an increase in consumption of SSRIs and MSs. This research has several limitations: (1) our sample is small and not representative of the entire Italian population; (2) despite a strong relationship between medications sales and their consumption is supposed, this relationship is not fully demonstrated; (3) we measured only the three most common classes of psychotropic medications used in the treatment of anxietydepressive spectrum but not other antidepressant or antipsychotic medications; and (4) we recorded only medication rate sales, and we do not know if the surge is due to an increase in new cases, the worsening of pre-existing sufferings or both. Because of these limitations and the rapidly evolving nature of COVID-19 pandemic psychological burden, our results must be considered preliminary. Overall, our findings are in line with previous reviews and metaanalyses 1e3 that suggest an increased prevalence of mental burden due to the COVID-19 pandemic and recommend the urgent need of investments on preventive measures and health-promoting interventions (e.g. psychotherapies) to buffer negative effects of COVID-19 on mental health. 10 Author contributions B.F. conceptualization; methodology; analysis and interpretation; writingdoriginal draft. C.M. conceptualization; data curation; methodology; writingdreview and editing. E.D.R. conceptualization; data curation; methodology; writingdreview and editing G.A.C conceptualization; data curation; methodology; writingdreview and editing R.S. conceptualization; data curation; methodology; C.I. conceptualization; supervision; methodology; analysis and interpretation; writingdoriginal draft. None declared. None declared. None declared. The prevalence of psychiatric comorbidities during the SARS and COVID-19 epidemics: a systematic review and meta-analysis of observational studies Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis Mental burden and its risk and protective factors during the early phase of the SARS-CoV-2 pandemic: systematic review and meta-analyses Antidepressants, primary care, and adult mental health services in England during COVID-19 Increased prescribing of psychotropic medications to ontario nursing home residents during the COVID-19 pandemic Trends in antidepressant prescribing in England Agenzia Italiana del Farmaco COVID-19: second wave or multiple peaks, natural herd immunity or vaccineewe should be prepared The COVID-19 pandemic brings a second wave of social isolation and disrupted services Global storm of stress-related psychopathological symptoms: a brief overview on the usefulness of virtual reality in facing the mental health impact of COVID-19